Document Detail


Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole.
MedLine Citation:
PMID:  15448612     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: One well-known extraesophageal manifestation of gastroesophageal reflux disease (GERD) is chronic laryngitis. The aim of this study was to estimate the efficiency of eight weeks of treatment with the PPI rabeprazole in a selected group of patients with chronic idiopathic laryngitis without typical GERD symptoms.
MATERIAL/METHODS: Seventeen patients (nine men and eight women) aged 35-72 years, with long histories (0.5 to 6 years) of chronic idiopathic laryngitis were included in the study. Larynx appearance was estimated by laryngostroboscopy. This examination, as well as interview and physical examination were performed in all patients at the start of the study and after 8 weeks of treatment with 20 mg rabeprazole taken orally twice a day.
RESULTS: There was remarkably good therapeutic outcome, clinical symptoms such as hoarseness and pharyngeal pain resolved, respectively, in 68.7 and 78.5% of patients and laryngeal signs in 50-80%, except for weak tension of the vocal cords which was observed in 12 patients at the start and end of the study.
CONCLUSIONS: Treatment with a proton pump inhibitor can be considered as a first-line diagnostic and therapeutic method in patients with idiopathic chronic laryngitis. Weak tension of vocal cords was often seen in these patients and persisted after the 8-week-long treatment.
Authors:
Maria Kłopocka; Anna Sinkiewicz; Jacek Budzyński; Grzegorz Pulkowski; Maciej Swiatkowski
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2004-09-23
Journal Detail:
Title:  Medical science monitor : international medical journal of experimental and clinical research     Volume:  10     ISSN:  1234-1010     ISO Abbreviation:  Med. Sci. Monit.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-06     Completed Date:  2005-06-24     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  9609063     Medline TA:  Med Sci Monit     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  PI115-8     Citation Subset:  IM    
Affiliation:
The Ludwik Rydygier University of Medicine, Bydgoszcz, Poland. mariaklopocka@wp.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Adult
Aged
Benzimidazoles / administration & dosage*,  therapeutic use*
Chronic Disease / drug therapy
Female
Humans
Laryngitis / drug therapy*
Male
Middle Aged
Omeprazole / administration & dosage*,  analogs & derivatives*,  therapeutic use*
Questionnaires
Time Factors
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Benzimidazoles; 32828355LL/rabeprazole; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intrathecal labor analgesia using levobupivacaine 2.5 mg with fentanyl 25 microg--would half the dos...
Next Document:  Selective potentiation of proximal processes: neurobiological mechanisms for spread of activation.